Synonyms: TFRC, CD71
Anti-TfR (Jr-141), is an antibody targeting human transferrin receptor (hTfR). It can be used in treatment of patients with mucopolysaccharidosis II (MPS II) and CNS disorders. MW :146.02 KD.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Anti-TfR (Jr-141), is an antibody targeting human transferrin receptor (hTfR). It can be used in treatment of patients with mucopolysaccharidosis II (MPS II) and CNS disorders. MW :146.02 KD.
|
References |
|---|
| Isotype | Human IgG1 |
|---|---|
| Source | CHO |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT04348136 | ACTIVE_NOT_RECRUITING | Drug: JR-141 | Mucopolysaccharidosis II | JCR Pharmaceuticals Co., Ltd. | 2019-09-01 | PHASE2; PHASE3 |
| NCT05594992 | ENROLLING_BY_INVITATION | Drug: JR-141 | Mucopolysaccharidosis II | JCR Pharmaceuticals Co., Ltd. | 2023-02-22 | PHASE3 |
| NCT04573023 | ACTIVE_NOT_RECRUITING | Drug: JR-141|Drug: Idursulfase|Drug: JR-141 or Idursulfase | Mucopolysaccharidosis II | JCR Pharmaceuticals Co., Ltd. | 2022-02-14 | PHASE3 |
| NCT03708965 | ACTIVE_NOT_RECRUITING | Drug: JR-141 | Mucopolysaccharidosis II | JCR Pharmaceuticals Co., Ltd. | 2019-01-01 | PHASE2 |
| NCT03568175 | COMPLETED | Drug: JR-141 | Mucopolysaccharidosis II | JCR Pharmaceuticals Co., Ltd. | 2018-08-01 | PHASE2; PHASE3 |
| NCT03359213 | COMPLETED | Drug: JR-141|Drug: JR-141|Drug: JR-141 | Mucopolysaccharidosis II | JCR Pharmaceuticals Co., Ltd. | 2018-07-26 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-09-03)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.